Efficacy of the dietary histone deacetylase inhibitor butyrate alone or in combination with vitamin A against proliferation of MCF-7 human breast cancer cells

Brazilian Journal of Medical and Biological Research

Volumn 45, Issue 9, 2012, Pages 841-850

  Andrade, F O ^a   Nagamine, M K ^a   De Conti, A ^a   Chaible, L M ^a   Fontelles, C C ^a   Jordao Jr A A ^a   Vannucchi, H ^a   Dagli, M L Z ^a   Bassoli, B K ^a   Moreno, F S ^a   Ong, T P ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Breast cancer; Butyric acid; Epigenetics; MCF 7 cells; Vitamin A

Indexed keywords

BUTYRIC ACID; COMPLEMENTARY DNA; DNA; GENOMIC DNA; HISTONE DEACETYLASE INHIBITOR; HISTONE H3; RETINOID; RETINOL PALMITATE; RNA; SHORT CHAIN FATTY ACID;

ARTICLE; BREAST CANCER; CANCER CELL; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CONTROLLED STUDY; DNA CONTENT; DNA METHYLATION; EPIGENETICS; FLOW CYTOMETRY; GROWTH INHIBITION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HISTONE ACETYLATION; HUMAN; HUMAN CELL; REAL TIME POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

EID: 84865397256     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2012007500103     Document Type: Article

References (38)

1. WHO-World Health Organization. World Health Statistics. Geneva: World Health Organization; 2008.
2. Sun J, Xu X, Liu J, Liu H, Fu L, Gu L. Epigenetic regulation of retinoic acid receptor beta2 gene in the initiation of breast cancer. Med Oncol 2011; 28: 1311-1318.
3. Veeck J, Esteller M. Breast cancer epigenetics: from DNA methylation to microRNAs. J Mammary Gland Biol Neoplasia 2010; 15: 5-17.
4. Kelly TK, De Carvalho DD, Jones PA. Epigenetic modifications as therapeutic targets. Nat Biotechnol 2010; 28: 1069-1078.
5. Ross SA. Nutritional genomic approaches to cancer prevention research. Exp Oncol 2007; 29: 250-256.
6. Kuroiwa-Trzmielina J, de Conti A, Scolastici C, Pereira D, Horst MA, Purgatto E, et al. Chemoprevention of rat hepatocarcinogenesis with histone deacetylase inhibitors: efficacy of tributyrin, a butyric acid prodrug. Int J Cancer 2009; 124: 2520-2527.
7. Link A, Balaguer F, Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem Pharmacol 2010; 80: 1771-1792.
8. Delage B, Dashwood RH. Dietary manipulation of histone structure and function. Annu Rev Nutr 2008; 28: 347-366.
9. de Conti A, Kuroiwa-Trzmielina J, Horst MA, Bassoli BK, Chagas CE, Purgatto E, et al. Chemopreventive effects of the dietary histone deacetylase inhibitor tributyrin alone or in combination with vitamin A during the promotion phase of rat hepatocarcinogenesis. J Nutr Biochem 2012; 23: 860-866.
10. Miller AA, Kurschel E, Osieka R, Schmidt CG. Clinical pharmacology of sodium butyrate in patients with acute leukemia. Eur J Cancer Clin Oncol 1987; 23: 1283-1287.
11. Conley BA, Egorin MJ, Tait N, Rosen DM, Sausville EA, Dover G, et al. Phase I study of the orally administered butyrate prodrug, tributyrin, in patients with solid tumors. Clin Cancer Res 1998; 4: 629-634.
12. Hamer HM, Jonkers D, Venema K, Vanhoutvin S, Troost FJ, Brummer RJ. Review article: the role of butyrate on colonic function. Aliment Pharmacol Ther 2008; 27: 104-119.
13. Belobrajdic DP, McIntosh GH. Dietary butyrate inhibits NMUinduced mammary cancer in rats. Nutr Cancer 2000; 36: 217-223.
14. De los Santos M, Martinez-Iglesias O, Aranda A. Anti-estrogenic actions of histone deacetylase inhibitors in MCF-7 breast cancer cells. Endocr Relat Cancer 2007; 14: 1021-1028.
15. Walker GE, Wilson EM, Powell D, Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 2001; 142: 3817-3827.
16. Chopin V, Toillon RA, Jouy N, Le Bourhis X. P21(WAF1/ CIP1) is dispensable for G1 arrest, but indispensable for apoptosis induced by sodium butyrate in MCF-7 breast cancer cells. Oncogene 2004; 23: 21-29.
17. Simeone AM, Tari AM. How retinoids regulate breast cancer cell proliferation and apoptosis. Cell Mol Life Sci 2004; 61: 1475-1484.
18. Hayden LJ, Satre MA. Alterations in cellular retinol metabolism contribute to differential retinoid responsiveness in normal human mammary epithelial cells versus breast cancer cells. Breast Cancer Res Treat 2002; 72: 95-105.
19. Esteller M, Guo M, Moreno V, Peinado MA, Capella G, Galm O, et al. Hypermethylation-associated Inactivation of the Cellular Retinol-Binding-Protein 1 Gene in Human Cancer. Cancer Res 2002; 62: 5902-5905.
20. Mira YL, Zheng WL, Kuppumbatti YS, Rexer B, Jing Y, Ong DE. Retinol conversion to retinoic acid is impaired in breast cancer cell lines relative to normal cells. J Cell Physiol 2000; 185: 302-309.
21. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011; 6: 345-364.
22. Farias EF, Ong DE, Ghyselinck NB, Nakajo S, Kuppumbatti YS, Lopez R. Cellular retinol-binding protein I, a regulator of breast epithelial retinoic acid receptor activity, cell differentiation, and tumorigenicity. J Natl Cancer Inst 2005; 97: 21-29.
23. Spurling CC, Suhl JA, Boucher N, Nelson CE, Rosenberg DW, Giardina C. The short chain fatty acid butyrate induces promoter demethylation and reactivation of RARbeta2 in colon cancer cells. Nutr Cancer 2008; 60: 692-702.
24. Sirchia SM, Ren M, Pili R, Sironi E, Somenzi G, Ghidoni R, et al. Endogenous reactivation of the RARbeta2 tumor suppressor gene epigenetically silenced in breast cancer. Cancer Res 2002; 62: 2455-2461.
25. Jeong J, Adamson LK, Hatam R, Greenhalgh DG, Cho K. Alterations in the expression and modification of histones in the liver after injury. Exp Mol Pathol 2003; 75: 256-264.
26. Druesne-Pecollo N, Chaumontet C, Pagniez A, Vaugelade P, Bruneau A, Thomas M, et al. In vivo treatment by diallyl disulfide increases histone acetylation in rat colonocytes. Biochem Biophys Res Commun 2007; 354: 140-147.
27. Alyaqoub FS, Tao L, Kramer PM, Steele VE, Lubet RA, Gunning WT, et al. Prevention of mouse lung tumors and modulation of DNA methylation by combined treatment with budesonide and R115777 (Zarnestra MT). Carcinogenesis 2007; 28: 124-129.
28. Goldenberg D, Harden S, Masayesva BG, Ha P, Benoit N, Westra WH, et al. Intraoperative molecular margin analysis in head and neck cancer. Arch Otolaryngol Head Neck Surg 2004; 130: 39-44.
29. Murray M, Butler AM, Martini R. Inhibition of microsomal 17 beta-hydroxysteroid oxidoreduction activities in rat liver by all-trans-, 9-cis-and 13-cis-retinoic acid. Biochim Biophys Acta 1994; 1222: 227-233.
30. Mongan NP, Gudas LJ. Valproic acid, in combination with all-trans retinoic acid and 5-aza-2'-deoxycytidine, restores expression of silenced RARbeta2 in breast cancer cells. Mol Cancer Ther 2005; 4: 477-486.
31. Rahim R, Strobl JS. Hydroxychloroquine, chloroquine, and all-trans retinoic acid regulate growth, survival, and histone acetylation in breast cancer cells. Anticancer Drugs 2009; 20: 736-745.
32. Ocker M, Schneider-Stock R. Histone deacetylase inhibitors: signalling towards p21cip1/waf1. Int J Biochem Cell Biol 2007; 39: 1367-1374.
33. Tryndyak VP, Kovalchuk O, Pogribny IP. Loss of DNA methylation and histone H4 lysine 20 trimethylation in human breast cancer cells is associated with aberrant expression of DNA methyltransferase 1, Suv4-20h2 histone methyltransferase and methyl-binding proteins. Cancer Biol Ther 2006; 5: 65-70.
34. Shann YJ, Cheng C, Chiao CH, Chen DT, Li PH, Hsu MT. Genome-wide mapping and characterization of hypomethylated sites in human tissues and breast cancer cell lines. Genome Res 2008; 18: 791-801.
35. Arapshian A, Kuppumbatti YS, Lopez R. Methylation of conserved CpG sites neighboring the beta retinoic acid response element may mediate retinoic acid receptor beta gene silencing in MCF-7 breast cancer cells. Oncogene 2000; 19: 4066-4070.
36. Cho YH, Shen J, Gammon MD, Zhang YJ, Wang Q, Gonzalez K, et al. Prognostic significance of gene-specific promoter hypermethylation in breast cancer patients. Breast Cancer Res Treat 2012; 131: 197-205.
37. Widschwendter M, Berger J, Muller HM, Zeimet AG, Marth C. Epigenetic downregulation of the retinoic acid receptorbeta2 gene in breast cancer. J Mammary Gland Biol Neoplasia 2001; 6: 193-201.
38. Arapshian A, Bertran S, Kuppumbatti YS, Nakajo S, Lopez R. Epigenetic CRBP downregulation appears to be an evolutionarily conserved (human and mouse) and oncogene-specific phenomenon in breast cancer. Mol Cancer 2004; 3: 13.